Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.

A number of other analysts also recently issued reports on the company. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Northland Securities reissued a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

ONCT stock opened at $0.53 on Monday. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14. The stock has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. The business has a fifty day moving average of $0.83 and a two-hundred day moving average of $3.02.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.